INTRODUCTION
Cushing's disease (CD) is a rare endocrine disorder characterized by endogenous hypercortisolism, which is associated with metabolic and psychiatric disorders. It is essential to understand the impact of normalization of serum cortisol in the evolution of these comorbidities.
OBJECTIVES PATIENTS AND METHODS

DISCUSSION AND CONCLUSION
Biochemical control of hypercortisolism seems to improve the associated metabolic and psychiatric disorders in CD.
However, as it is not possible to predict the evolution of these comorbidities it is mandatory an appropriate follow-up, evaluation and treatment of these patients.
To evaluate the evolution of metabolic and psychiatric disorders after biochemical control of hypercortisolism in patients with CD. 
